

Supplemental material

Sequential, response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis

Marco Basset, Paolo Milani, Mario Nuvolone, Francesca Benigna, Lara Rodigari, Andrea Foli, Giampaolo Merlini, Giovanni Palladini

Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, Italy.

Corresponding author:

Giovanni Palladini, M.D., Ph.D.

Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo

Viale Golgi, 19 – 27100 Pavia, Italy

e-mail: giovanni.palladini@unipv.it


Supplemental Table 1. Characteristics of 16 patients with AL amyloidosis who lost eligibility after ASCT.

| Variables | N (%) – median (IQR) |
|--|--|
| Age, years | 58 (52-63) |
| Sex, male | 9 (57) |
| Organ involvement Heart / Kidney / Liver / ST / ANS / PNS | 7 (43) / 10 (63) / 2 (13) / 4 (25) / - / - |
| More than 2 organs involved | - |
| Cardiac stage I / II / IIIa | 6 (37) / 9 (57) / 1 (6) |
| NT-proBNP, ng/L | 411 (174-1308) |
| Renal stage I / II / III [†] | 10 (70) / 6 (30) / - |
| Proteinuria, g/24h | 1.69 (0.67-5.71) |
| eGFR, mL/min per 1.72 m ² | 72 (61->90) |
| BMPC, % | 9 (5-20) |



ANS, autonomic nervous system; BMPC, bone marrow plasma cells; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal natriuretic pro-peptide type B; PNS, peripheral nervous system; ST, soft tissues.

*Cardiac stage based on troponins level and NT-proBNP: thresholds for cTnI and NT-proBNP are <0.1 ng/mL and <332 ng/L, respectively. Stage I both cTnI <0.1 ng/mL and NT-proBNP <332 ng/L; stage II either cTnI >0.1 ng/mL or NT-proBNP >332 ng/L; stage IIIa both cTnI >0.1 ng/mL and NT-proBNP >332 ng/L, with NT-proBNP <8500 ng/L; stage IIIb cTnI >0.1 ng/mL and NT-proBNP >332 ng/L, with NT-proBNP >8500 ng/L.


[†]Renal stage based on proteinuria and eGFR levels: thresholds for proteinuria >5 g/24h and eGFR <50 mL/min per 1.73 m². Stage I, both proteinuria ≤5 g/24h and eGFR ≥50 mL/min per 1.73 m²; stage II, either proteinuria >5 g/24h or eGFR <50 mL/min per 1.73 m²; stage III, both proteinuria >5 g/24h and eGFR <50 mL/min per 1.73 m².



Supplemental figure 1. Landmark plotted OS in patients treated with CyBorD and ASCT and in those who received CyBorD alone. 6-month landmark OS for CyBorD alone: 5-years OS 85% (A); 6-month landmark OS for CyBorD and ASCT: 5-years OS 84% (B); 12-month landmark OS for CyBorD alone: 5-years OS 91% (C); 12-month landmark OS for CyBorD and ASCT: 5-years OS 90% (D)



Supplemental figure 2. TNTD in patients that achieved a CR after CyBorD and ASCT or only induction therapy with CyBorD. 6-month landmark TNTD in patients treated with CyBorD alone (A); 6-month landmark TNTD in patients treated with CyBorD and ASCT



Supplemental figure 3. OS in patients who did not achieve a satisfactory response after CyBorD and received a rescue treatment different from ASCT